Biomotion Sciences Ordinary SharesSLXN
...Loading SLXN Peers...
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Employees
CEO : Mr. Ilan Hadar M.B.A.
Address : The Goldyne Savad Institute of Gene Therapy, Jerusalem, IL, - 9112001,
| Key Excutives | Designation |
|---|---|
| Ms. Mirit Horenshtein Hadar | EVice President of Finance Affairs, Chief Financial Officer & Secretary |
| Mr. Ilan Hadar M.B.A. | Chairman & Chief Executive Officer |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific & Development Officer |